COVID-19 outcomes in people living with HIV: Peering through the waves

Imagem de Miniatura
Arquivos
art_SALES_COVID19_outcomes_in_people_living_with_HIV_Peering_2023.PDF (691.43 KB)
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER ESPANA
Autores
SALES, Thais Lorenna Souza
SOUZA-SILVA, Maira Viana Rego
DELFINO-PEREIRA, Polianna
NEVES, Joao Victor Baroni
SACIOTO, Manuela Furtado
ASSIS, Vivian Costa Morais de
DUANI, Helena
OLIVEIRA, Neimy Ramos de
SAMPAIO, Natalia da Cunha Severino
RAMOS, Lucas Emanuel Ferreira
Citação
CLINICS, v.78, article ID 100223, 8p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective: To evaluate clinical characteristics and outcomes of COVID-19 patients infected with HIV, and to compare with a paired sample without HIV infection. Methods: This is a substudy of a Brazilian multicentric cohort that comprised two periods (2020 and 2021). Data was obtained through the retrospective review of medical records. Primary outcomes were admission to the intensive care unit, invasive mechanical ventilation, and death. Patients with HIV and controls were matched for age, sex, number of comorbidities, and hospital of origin using the technique of propensity score matching (up to 4:1). They were compared using the Chi-Square or Fisher's Exact tests for categorical variables and the Wilcoxon for numerical variables. Results: Throughout the study, 17,101 COVID-19 patients were hospitalized, and 130 (0.76%) of those were infected with HIV. The median age was 54 (IQR: 43.0;64.0) years in 2020 and 53 (IQR: 46.0;63.5) years in 2021, with a predominance of females in both periods. People Living with HIV (PLHIV) and their controls showed similar prevalence for admission to the ICU and invasive mechanical ventilation requirement in the two periods, with no significant differences. In 2020, in-hospital mortality was higher in the PLHIV compared to the controls (27.9% vs. 17.7%; p = 0.049), but there was no difference in mortality between groups in 2021 (25.0% vs. 25.1%; p > 0.999). Conclusions: Our results reiterate that PLHIV were at higher risk of COVID-19 mortality in the early stages of the pandemic, however, this finding did not sustain in 2021, when the mortality rate is similar to the control group.
Palavras-chave
COVID-19, HIV, Intensive care unit, Mechanical ventilation, Mortality
URI
https://observatorio.fm.usp.br/handle/OPI/56319
Referências
  1. [Anonymous], 1996, DISPOE DISTRIBUI CAO
  2. Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764
  3. Berenguer J, 2021, CLIN MICROBIOL INFEC, V27, P1678, DOI 10.1016/j.cmi.2021.06.023
  4. Bertagnolio S, 2022, LANCET HIV, V9, pE486, DOI 10.1016/S2352-3018(22)00097-2
  5. Chien MC, 2020, J PROTEOME RES, V19, P4690, DOI [10.1021/acs.jproteome.0c00392, 10.1101/2020.03.18.997585]
  6. Danwang C, 2022, AIDS RES THER, V19, DOI 10.1186/s12981-021-00427-y
  7. Davanzo GG, 2020, PREPRINT
  8. Dong YH, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000026573
  9. Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
  10. Etienne N, 2020, AIDS, V34, P1771, DOI 10.1097/QAD.0000000000002651
  11. Frater J, 2021, LANCET HIV, V8, pE474, DOI 10.1016/S2352-3018(21)00103-X
  12. Geretti AM, 2021, CLIN INFECT DIS, V73, pE2095, DOI 10.1093/cid/ciaa1605
  13. Hoffmann C, 2021, HIV MED, V22, P372, DOI 10.1111/hiv.13037
  14. Inciarte A, 2020, AIDS, V34, P1775, DOI 10.1097/QAD.0000000000002643
  15. Jassat W, 2021, LANCET HIV, V8, pE554, DOI 10.1016/S2352-3018(21)00151-X
  16. Jiang HB, 2020, LANCET HIV, V7, pE308, DOI 10.1016/S2352-3018(20)30105-3
  17. Kouhpayeh H, 2021, EUR J TRANSL MYOL, V31, DOI 10.4081/ejtm.2021.10107
  18. Lee KW, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18073554
  19. Liu NP, 2021, CELL REP, V37, DOI 10.1016/j.celrep.2021.109793
  20. Maciel RA, 2018, INT J INFECT DIS, V70, P30, DOI 10.1016/j.ijid.2018.02.009
  21. Madzime M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.634386
  22. Marcolino MS, 2021, INT J INFECT DIS, V107, P300, DOI 10.1016/j.ijid.2021.01.019
  23. Mdege ND, 2017, LANCET GLOB HEALTH, V5, pE578, DOI 10.1016/s2214-109x(17)30170-5
  24. Melchjorsen J, 2011, JAIDS-J ACQ IMM DEF, V57, P265, DOI 10.1097/QAI.0b013e3182185276
  25. Mellor MM, 2021, AIDS, V35, pF1, DOI 10.1097/QAD.0000000000002836
  26. Nomah DK, 2021, LANCET HIV, V8, pE701, DOI 10.1016/S2352-3018(21)00240-X
  27. Oyelade T, 2022, TROP MED INFECT DIS, V7, DOI 10.3390/tropicalmed7020022
  28. Pablos-Méndez A, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2939
  29. Aliberti MJR, 2021, AGE AGEING, V50, P32, DOI 10.1093/ageing/afaa240
  30. Ssentongo P, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-85359-3
  31. Sun J, PREPRINT
  32. UNAIDS-Joint United Nations Programme on HIV/AIDS, 2022, COUNTR FACTSH BRAZ 2
  33. WHO, 2021, CONS GUID HIV PREV T
  34. WHO-World Health Organization, 2022, CUM CONF PROB COVID
  35. World Health Organization, 2021, WHO CORONAVIRUS DIS
  36. Yang XY, 2021, LANCET HIV, V8, pE690, DOI 10.1016/S2352-3018(21)00239-3
  37. Zahid MN, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18105350
  38. Zhao QW, 2020, J MED VIROL, V92, P1915, DOI 10.1002/jmv.25889

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - LIM/66
Artigos e Materiais de Revistas Científicas - ODS/03